Phathom Pharmaceuticals, INC Form 4 insider transactions

Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, Inc., reported a transaction in 1,555 shares of common stock on July 14, 2026.

Phathom Pharmaceuticals Director Asit Parikh reported a transfer of 28,000 common shares to a trust for his spouse's benefit.

Director Asit Parikh acquired 24,122 restricted stock units and exercised options for 17,500 shares of Phathom Pharmaceuticals.

James N. Topper, a Director and 10% owner of Phathom Pharmaceuticals, Inc., acquired 24,122 Restricted Stock Units (RSUs) on May 19, 2026.

Phathom Pharmaceuticals, Inc. reports that Director Mark Stenhouse was granted Restricted Stock Units (RSUs) on May 19, 2026, with vesting contingent on continued service.

Heidi Fields, a Director at Phathom Pharmaceuticals, Inc., acquired 24,122 shares of common stock through Restricted Stock Units on May 19, 2026.

Michael F. Cola, a Director at Phathom Pharmaceuticals, Inc., acquired 24,122 shares of common stock through Restricted Stock Units (RSUs) granted on May 19, 2026.

Phathom Pharmaceuticals, Inc. reports that Director Frank Karbe acquired 24,122 Restricted Stock Units (RSUs) on May 19, 2026, under the company's Non-Employee Director Compensation Program.

Theodore R. Schroeder, a Director at Phathom Pharmaceuticals, Inc., was granted Restricted Stock Units (RSUs) representing 24,122 shares of common stock.

Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, reported the acquisition of restricted stock units and performance-based shares, alongside tax-related share dispositions.

Phathom Pharmaceuticals' Chief Legal Officer, Anne Marie Cook, reported the acquisition of shares from vested performance units and the disposition of shares for tax withholding.

Phathom Pharmaceuticals CEO Steven L. Basta reported the vesting of performance stock units and a subsequent sale of shares to cover tax obligations.

Phathom Pharmaceuticals Director Asit Parikh transferred 80,500 shares of common stock to a trust for his spouse, maintaining indirect beneficial ownership.

Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, disposed of 776 shares of common stock to cover tax withholding obligations.

Phathom Pharmaceuticals Director Asit Parikh exercised options to acquire 8,750 shares of common stock at $10.30 per share, increasing direct ownership.

Phathom Pharmaceuticals' President and CEO, Steven L. Basta, was granted 251,034 restricted stock units and options for 226,156 shares, effective January 2, 2026.

Phathom Pharmaceuticals' Chief Legal Officer, Anne Marie Cook, received grants of restricted stock units and stock options.

Phathom Pharmaceuticals' Chief Financial Officer, Sanjeev Narula, was granted 82,715 restricted stock units and options for 42,848 shares of common stock.

Phathom Pharmaceuticals director Asit Parikh exercised options to acquire 8,750 shares of common stock at $10.30 per share in a pre-planned transaction.

Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, disposed of 230 common shares to cover tax withholding obligations.

Phathom Pharmaceuticals' Chief Legal Officer, Anne Marie Cook, reported the future vesting of performance stock units and subsequent sale of shares for tax withholding, scheduled for December 17, 2025.

Phathom Pharmaceuticals CEO Steven Basta increased his direct ownership by 30,536 shares after performance stock unit vesting and tax-related share surrender.

Phathom Pharmaceuticals CEO Steven L. Basta exercised performance stock units and sold a portion of the resulting common stock to cover tax obligations.

Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, sold 524 shares of common stock to cover tax withholding obligations.

Phathom Pharmaceuticals' Chief Financial and Business Officer, Sanjeev Narula, reported the acquisition of 144,000 restricted stock units via an amended SEC filing.

Phathom Pharmaceuticals' Chief Financial and Business Officer, Sanjeev Narula, received a grant of 200,000 stock options with an exercise price of $11.61.

Phathom Pharmaceuticals CEO Steven L. Basta reported the vesting of 90,000 performance stock units and the subsequent disposition of shares for tax withholding.

Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, sold 461 shares of common stock to cover tax withholding obligations.

Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, has filed a Form 4 indicating a future sale of 1,692 shares of common stock on July 16, 2025, to cover tax withholding obligations from restricted stock unit settlements.

Anne Marie Cook, Chief Legal Officer and Corporate Secretary of Phathom Pharmaceuticals, Inc., was granted 210,000 stock options with an exercise price of $9.47, vesting over four years.